Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding Gain Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 19 | 16 | −3 |
| Shares | 1.06M | 1.16M | +106.0K (+10.0%) |
| Value | $5.71M | $4.75M | −$959.0K (−16.8%) |
New holders (1)
Institutions that held Gain Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 11,722 | $48.0K | 0.00% |
Sold out (4)
Institutions that held Gain Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Two Sigma Investments, LP | 19,467 | $106.0K |
| Susquehanna International Group, LLP | 19,357 | $103.0K |
| Citadel Advisors LLC | 13,029 | $70.0K |
| Banque Cantonale Vaudoise | 3,000 | $16.0K |